[go: up one dir, main page]

PE20060627A1 - Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 - Google Patents

Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2

Info

Publication number
PE20060627A1
PE20060627A1 PE2005001028A PE2005001028A PE20060627A1 PE 20060627 A1 PE20060627 A1 PE 20060627A1 PE 2005001028 A PE2005001028 A PE 2005001028A PE 2005001028 A PE2005001028 A PE 2005001028A PE 20060627 A1 PE20060627 A1 PE 20060627A1
Authority
PE
Peru
Prior art keywords
alkyl
pirazole
agonists
cannabinoid receptors
substituted
Prior art date
Application number
PE2005001028A
Other languages
English (en)
Inventor
Francis Barth
Christian Congy
Claude Vernhet
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20060627A1 publication Critical patent/PE20060627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIRAZOL DE FORMULA I, DONDE A ES ALQUILENO C3-C5, CH2-CH2-O-CH2, ENTRE OTROS; W ES UN ENLACE DIRECTO O CH2; R1 ES H O ALQUILO C1-C3; R2 ES ALQUILO C1-C10, B-R4, ENTRE OTROS; R3 ES FENILO SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ENTRE OTROS; B ES UN ENLACE DIRECTO, ALQUILENO C1-C2, ENTRE OTROS; R4 ES FENILO NO SUSTITUIDO O SUSTITUIDO POR UNO O VARIOS SUSTITUYENTES SELECCIONADOS DE HALOGENO, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-1-ADAMANTIL-1-(3,4-DICLOROFENIL)-1,4,5,6-TETRAHIDROCICLOPENTA[c]PIRAZOL-3-CARBOXAMIDA, N-[(1S)-1-CICLOHEXILETIL]-1-(3,4-DICLOROFENIL)-6,6-DIMETIL-1,4,5,6-TETRAHIDROCICLOPENTA[c]PIRAZOL-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES CANNABINOIDES CB1 Y/O CB2 Y SON UTILES PARA EL TRATAMIENTO DE LA MIGRANA, ESTRES, ENFERMEDADES DE ORIGEN PSICOSOMATICO, LESIONES DE MEDULA ESPINAL, ENTRE OTRAS
PE2005001028A 2004-09-13 2005-09-06 Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 PE20060627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0409712A FR2875230A1 (fr) 2004-09-13 2004-09-13 Derives de pyrazole condense, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20060627A1 true PE20060627A1 (es) 2006-08-15

Family

ID=34954413

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001028A PE20060627A1 (es) 2004-09-13 2005-09-06 Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2

Country Status (6)

Country Link
AR (1) AR051288A1 (es)
FR (1) FR2875230A1 (es)
PE (1) PE20060627A1 (es)
TW (1) TW200621786A (es)
UY (1) UY29112A1 (es)
WO (1) WO2006030124A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
AU2006253842A1 (en) * 2005-06-02 2006-12-07 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2007001939A1 (en) * 2005-06-27 2007-01-04 Janssen Pharmaceutica N.V. Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities
US8378096B2 (en) 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
AU2006292051B2 (en) * 2005-09-23 2012-11-15 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
AU2006295130A1 (en) * 2005-09-23 2007-04-05 Janssen Pharmaceutica, N.V. Tetrahydro-indazolyl cannabinoid modulators
DK1931335T3 (da) 2005-09-23 2010-06-07 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl-pyrazol-cannabinoid-modulatorer
US7825151B2 (en) 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
JP2009508953A (ja) * 2005-09-23 2009-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロ−シクロヘプタピラゾール系カンナビノイドモジュレーター
WO2007095513A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica, Nv Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
EP2139326A4 (en) * 2007-03-21 2011-06-15 Janssen Pharmaceutica Nv METHOD OF TREATING PAIN INDUCED BY A CB2 RECEPTOR
AU2008229265A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating CB2 receptor mediated pain
EP2269990A4 (en) * 2008-03-25 2012-04-18 Takeda Pharmaceutical Heterocyclic compound
WO2010088050A2 (en) * 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN102596913B (zh) * 2009-08-28 2016-11-09 艾尼纳制药公司 大麻素受体调节剂
DK3252057T3 (da) 2009-12-04 2024-06-17 Sunovion Pharmaceuticals Inc Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) * 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
BR112013021549B1 (pt) 2011-02-25 2022-01-11 Arena Pharmaceuticals, Inc Processos para preparação de forma cristalina anidra, para preparação de composição farmacêutica e para preparação de forma de dosagem, forma cristalina não solvatada anidra, composição farmacêutica, forma de dosagem, uso da referida forma cristalina e solvato
EP2847180B1 (en) * 2012-05-11 2017-01-04 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
CN110678205B (zh) 2017-02-16 2023-05-23 桑诺维恩药品公司 治疗精神分裂症的方法
EA201992638A1 (ru) 2017-05-08 2020-03-18 Арена Фармасьютикалз, Инк. Соединения и способы для лечения висцеральной боли
KR20200036008A (ko) 2017-08-02 2020-04-06 선오비온 파마슈티컬스 인코포레이티드 이소크로만 화합물 및 이의 용도
JP7453148B2 (ja) 2018-02-16 2024-03-19 サノビオン ファーマシューティカルズ インク 塩、結晶形態、およびその製造方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2021047583A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种三环吡唑衍生物及其制备
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
MX2022012833A (es) 2020-04-14 2022-11-07 Sunovion Pharmaceuticals Inc (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-n-metilmetanamina para tratar trastornos neurologicos y psiquiatricos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
EP1448557A4 (en) * 2001-10-26 2005-02-02 Univ Connecticut HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications

Also Published As

Publication number Publication date
WO2006030124A1 (fr) 2006-03-23
UY29112A1 (es) 2006-04-28
TW200621786A (en) 2006-07-01
AR051288A1 (es) 2007-01-03
FR2875230A1 (fr) 2006-03-17

Similar Documents

Publication Publication Date Title
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
PE20070336A1 (es) Compuestos de indolina como agonistas de receptores adrenergicos alfa2c funcionalmente selectivos
UA84022C2 (ru) Производные (тио)карбамоилциклогексана как антагонисты d3/d2 рецептора
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
EA200401282A1 (ru) Пиридиноилпиперидины как агонисты 5-ht1f
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
DE602005020655D1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonisten
EA200300453A1 (ru) Производные 3-ароилиндола и их применение в качестве агонистов рецепторов cb2
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
PE20040946A1 (es) Compuestos de pirazolotriazina como ligandos del receptor cannabinoide
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
AR051461A1 (es) Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
NO20071476L (no) Antidiuretiske midler.
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
PE20140968A1 (es) Derivados de benzamida sustituida
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20081781A1 (es) Agonistas de adrenoreceptores alfa2c funcionalmente selectivos
PE20071224A1 (es) Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1)
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal